Astodrimer

Drug Profile

Astodrimer

Alternative Names: 3% w/w SPL7013 Gel; Astodrimer sodium; BRI-7013; SPL-7013; SPL7013 vaginal gel; VivaGel

Latest Information Update: 13 Jan 2017

Price : $50

At a glance

  • Originator Biomolecular Research Institute
  • Developer Starpharma
  • Class Antibacterials; Antivirals; Dendrimers; Peptides
  • Mechanism of Action Anion transport protein modulators; Surface antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Bacterial vaginosis; HIV infections
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Bacterial vaginosis
  • Phase I/II Herpes simplex virus infections; HIV infections
  • Research Human papillomavirus infections; Zika virus infection

Most Recent Events

  • 11 Jan 2017 Astodrimer receives Fast Track designation for Bacterial vaginosis [Vaginal,Gel] (Prevention, Treatment) in USA
  • 11 Jan 2017 Astodrimer receives Qualified Infectious Disease Product status for Bacterial vaginosis (Prevention, Treatment) in USA
  • 05 May 2016 Early research in Zika virus infection in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top